Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 19, 2013

Selexys commences SUSTAIN Phase II trial of SelG1 in sickle cell patients with pain crises

Selexys Pharmaceuticals has commenced a SUSTAIN Phase II trial to assess SelG1, an investigational anti-P-selectin humanised monoclonal antibody, in sickle cell patients with pain crises.

sickle cell anaemia

Selexys Pharmaceuticals has commenced a SUSTAIN Phase II trial to assess SelG1, an investigational anti-P-selectin humanised monoclonal antibody, in sickle cell patients with pain crises.

The multicentre, randomised, placebo-controlled, double-blind, twelve-month study will assess the safety and efficacy of SelG1 with or without hydroxyurea therapy in the patient group.

SelG1 prevents small blood vessels from becoming blocked and reduces the occurrence and severity of pain crises, in addition to downstream complications, by preventing certain blood cells from binding to one another and to the blood vessel walls.

"Not only does it have the potential to improve the clinical outcomes in patients, its effects may be additive or synergistic with those of hydroxyurea, the only drug currently approved by the FDA for treatment of complications due to sickle cell disease."

University of North Carolina Hematology/Oncology division lead investigator and associate professor of medicine Dr Kenneth Ataga said, "Not only does it have the potential to improve the clinical outcomes in patients, its effects may be additive or synergistic with those of hydroxyurea, the only drug currently approved by the FDA for treatment of complications due to sickle cell disease."

Around 174 patients will be randomised with high dose SelG1, low dose SelG1 or placebo in the presence or absence of hydroxyurea therapy, the current standard of treatment.

SelG1’s effectiveness in reducing the rate of sickle cell-related pain crises in each active dose level compared to placebo will be evaluated in the study, which will be conducted in approximately 60 centres throughout the US.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Selexys president and CEO Dr Scott Rollins said, "The SUSTAIN study focuses on the ability of our novel anti-P-selectin antibody to reduce or prevent the occurrence of pain crises and thereby improve the lives of patients with sickle cell, a disease that largely affects African-Americans in the US."


Image: Sickle-cell disease is a genetic blood disorder with over dominance, characterised by red blood cells that assume an abnormal, rigid, sickle shape. Photo courtesy of Dr Graham Beards.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU